We invite those 18 to 85 years old who are experiencing involuntary movements in their face or other parts of their body- and suffer from schizophrenia, schizoaffective disorder, bipolar disorder, or mood disorder- to see if they qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia.
Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. Compensation for time and travel may also be available.
Participants will be screened for eligibility and if deemed eligible, will receive the medication for the study treatment period of 48 weeks (which includes 16 in-office visits and a follow-up appointment four weeks after completing study treatment). Throughout the study, participants will continue to receive regular general health check-ups and monitoring of TD symptoms.
Segal Institute will be conducting this clinical trial at 3 sites:
North Miami Outpatient Clinic
1065 Northeast 125th Street, Suite 417
North Miami, Florida 33161
Phone: (305) 722-8447
West Broward Outpatient Clinic
7481 West Oakland Park Boulevard, Suite 205
Lauderhill, FL 33319
Phone: (954) 990-6326
Charleston Outpatient Clinic
1483 Tobias Gadson Blvd, Suite 107
Charleston, SC 29407
Phone: (843) 576-6750
